Why did FDA send 13 warning letters to online ketamine sellers in a single day?

TL;DR

• On June 23, 2026, FDA's Center for Drug Evaluation and Research issued 13 warning letters in a single day to online sellers of unapproved ketamine products, per Argus HQ's warning letter database (as of July 11, 2026).
• All 13 letters cite the same core statutory bundle — FD&C Act sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) — and 10 of the 13 add 301(k).
• The sweep alone accounts for 13 of the 31 "unapproved new drug" warning letters (42%) in Argus's 2026 dataset, and roughly 8% of all 165 FDA warning letters tracked so far this year.
• Eleven of the 13 letters carry MARCS-CMS numbers packed into a narrow band, 725145 through 725156. The other two, numbered 722122 and 728919, fall well outside that block despite sharing the same June 23 issue date.
• None of the 13 targeted a licensed telehealth ketamine provider. Every recipient was a standalone e-commerce storefront selling directly to consumers, several with generic domain names like buyketaonline.com and ketaminestore.org.

Why Did FDA Send 13 Warning Letters to Online Ketamine Sellers in a Single Day?

Thirteen letters. One drug. One day.

On June 23, 2026, FDA's Center for Drug Evaluation and Research (CDER) sent warning letters to 13 different online sellers, each accused of the same thing: introducing unapproved, misbranded ketamine products into interstate commerce over the open web. No inspections. No facility visits. Each letter is built entirely from a review of what the website itself was selling and how it was selling it.

That's a sweep, not a coincidence — and the pattern underneath it tells you more about where FDA is pointed next than any single letter would.

Argus HQ's warning letter database currently tracks 165 FDA warning letters issued in 2026. Thirteen landing on the same calendar date, against the same drug, from the same review office, is not routine. It is the kind of clustering that shows up when an agency runs a coordinated internet-surveillance sweep rather than responding to individual complaints one at a time.

The 13 letters, side by side

(Statutory citations per Argus HQ's review of each letter's text, as ingested from fda.gov. FD&C Act = Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq.)

Note the timing gap: FDA issued all 13 letters on June 23, 2026, but did not post them publicly to fda.gov until July 7, 2026 — a two-week lag between issuance and disclosure that's worth building into any monitoring workflow that checks FDA's site on a set schedule rather than continuously.

The same six sections, thirteen times

Regulators don't usually write 13 letters from scratch. They write one legal template and fill in the company name. That's exactly what happened here.

Every one of the 13 letters cites section 505(a) of the FD&C Act, which prohibits introducing a new drug into interstate commerce without an approved application. Every letter also cites 502(f)(1) (labeling must bear adequate directions for use) and 503(b)(1) (certain drugs, ketamine among them, are restricted to sale under a practitioner's prescription because a layperson cannot safely self-administer them without supervision). Ten of the 13 add 301(k), which covers misbranding or adulteration of a drug component held for sale after shipment in interstate commerce.

That's not 13 separate legal theories. It's one theory, applied to 13 defendants who were doing functionally the same thing: selling ketamine — sometimes as ketamine HCL powder, sometimes as troches, sometimes as injectable vials — directly to U.S. consumers with no prescription requirement and no practitioner oversight in the checkout flow.

FDA's own language, repeated nearly verbatim across the letters, makes the underlying concern explicit. From the letter to Ketacyn Pharmaceuticals: "FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved versions online poses significant risk" (FDA warning letter to Ketacyn Pharmaceuticals, June 23, 2026).

Read that sentence carefully. FDA isn't saying ketamine itself is the problem — it names two FDA-approved formulations, KETALAR (injectable ketamine) and SPRAVATO (esketamine nasal spray), both of which carry restricted distribution requirements and, in SPRAVATO's case, a Risk Evaluation and Mitigation Strategy. The agency is saying the unsupervised, direct-to-consumer channel is the problem. That distinction matters for anyone building or auditing a ketamine-adjacent business, because it means "we sell an FDA-approved molecule" is not a defense if the distribution model strips out the supervision the approval was conditioned on.

Numbering tells its own story

FDA assigns each warning letter a MARCS-CMS tracking number sequentially as it's drafted internally, not in the order it's eventually posted. Eleven of the 13 ketamine letters carry numbers packed into a tight run: 725145, 725147 through 725156, skipping only 725146. That's the fingerprint of a single drafting batch, worked through by the same reviewers over a short window.

Two letters don't fit that pattern. Ketamine Troche Store is numbered 722122 — thousands of letters earlier in the sequence — and Ket Plug is numbered 728919, thousands later. Both were still issued June 23, 2026, alongside the other 11. The likeliest explanation: those two sites were flagged and drafted on a different timeline (possibly held for additional review, or queued from an earlier or later surveillance pass) but released in the same batch once cleared. It's a small detail, but it tells you FDA's internet-surveillance pipeline for unapproved drugs runs on a rolling basis, feeding a periodic release cycle rather than issuing every letter the moment it's finished.

Why ketamine, and why now

Ketamine enforcement isn't new, but the concentration is. Argus's database shows 31 "unapproved new drug" warning letters issued industry-wide in 2026 to date; this single sweep accounts for 13 of them — 42% of the category, in one day, against one drug class. For context, the same database shows 48 CGMP-citation letters and 35 general warning letters spread across dozens of individual facility inspections over the same period. Nothing else in the dataset clusters this tightly.

The context is public-health attention on ketamine that's been building for several years: expanded off-label use for treatment-resistant depression, a wave of ketamine infusion clinics and telehealth prescribing services, and a parallel rise in unsupervised recreational use that FDA itself flags in the letters as "increased interest in the use of ketamine products" (FDA warning letter to Ketacyn Pharmaceuticals, June 23, 2026). FDA-approved ketamine and esketamine products exist specifically because the agency judged the drug's risk profile — dissociation, sedation, abuse potential, cardiovascular effects — serious enough to require REMS-level controls and practitioner administration in most cases. A website selling ketamine HCL powder or troches with no prescription gate strips out every one of those controls.

That's the enforcement logic connecting this sweep to earlier waves Argus has covered, including the compounded GLP-1 telehealth marketing crackdown: FDA is not just policing whether a molecule is approved somewhere. It's policing whether the specific distribution channel preserves the safeguards the approval assumed. Direct-to-consumer e-commerce, by design, usually doesn't.

What this means if you touch ketamine, telehealth, or DTC drug sales

• A prescription requirement is not decoration. If your ordering flow lets a consumer complete checkout for a Schedule III, practitioner-supervised drug without a licensed prescriber actually reviewing and authorizing that specific order, section 503(b)(1) exposure exists regardless of what your terms of service say.
• "We only sell research chemicals" doesn't survive a labeling review. Several of the 13 letters cite 502(f)(1) even where the seller framed the product as not-for-human-consumption; FDA looked at how the product was marketed and used that, not the disclaimer, to find intended use as a drug.
• Generic, keyword-stuffed domain names are a targeting signal, not camouflage. Names like buyketaonline.com and ketaminestore.org read as SEO-optimized storefronts built to capture consumer search traffic — exactly the pattern FDA's internet surveillance program is built to find.
• Expect a lag between issuance and public posting. These letters were dated June 23 but not posted until July 7. If your compliance monitoring only checks FDA's warning letter page on a schedule, build in that lag; don't assume "not yet posted" means "not yet issued."
• A REMS on the reference drug raises the bar, not lowers it. SPRAVATO's REMS status was cited as a reason the unapproved competing products carried more risk, not less — the existence of a controlled, approved pathway makes the uncontrolled one look worse by comparison.

FAQ

How many warning letters did FDA send to online ketamine sellers on June 23, 2026?

FDA's Center for Drug Evaluation and Research sent 13 warning letters on June 23, 2026, to 13 different online sellers of ketamine products, per Argus HQ's warning letter database as of July 11, 2026.

What FD&C Act sections did FDA cite in the ketamine warning letter sweep?

All 13 letters cite FD&C Act sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a). Ten of the 13 also cite 301(k). None of the letters cite CGMP regulations under 21 CFR parts 210–211, since these are internet-surveillance letters, not inspection-based letters.

Are any FDA-approved ketamine products legal to sell online?

FDA has approved ketamine (KETALAR, injectable) and esketamine (SPRAVATO, nasal spray) for specific uses, both restricted to administration under practitioner supervision, with SPRAVATO subject to a Risk Evaluation and Mitigation Strategy. The June 23, 2026 letters targeted unapproved formulations — including ketamine HCL powder and troches — sold directly to consumers without a prescription-verification step, not the approved products themselves.

Were any of the 13 companies licensed telehealth ketamine providers?

No. Per the letters and the underlying website reviews in Argus's database, all 13 recipients operated as direct-to-consumer e-commerce storefronts rather than licensed telehealth platforms with practitioner oversight built into the ordering process.

Why did FDA wait until July 7, 2026 to post letters dated June 23, 2026?

FDA does not disclose its internal posting schedule, and the letters themselves don't explain the gap. Argus's database shows a consistent pattern across this dataset of warning letters becoming publicly visible on fda.gov roughly one to two weeks after their issuance date, which compliance teams should account for when relying on the public warning letter page as a monitoring source.

Sources: FDA warning letters to the 13 companies listed above, issued June 23, 2026, and posted to fda.gov July 7, 2026 (individual links in the table above). Aggregate figures per Argus HQ's warning letter database, current as of July 11, 2026. Byline: The Argus Regulatory Analysis Team. Published 2026-07-11.

Get FDA briefs — $99/mo →